Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.

Phase 1

Recruiting

Conditions: Healthy Volunteers
Influenza Vaccination
Respiratory Syncytial Virus Vaccination
Parainfluenza Vaccination
Human Metapneumovirus Vaccination

Interventions: Biological: TIV-HA formulation 1 at high dose
Biological: TIV-HA formulation 2 at high dose
Biological: TIV-HA Vaccine formulation 1 at low dose
Biological: TIV-HA formulation 2 at low dose
Biological: RSV/hMPV/PIV3 formulation 1 at high dose
Biological: RSV/hMPV/PIV3 formulation 2 at high dose
Biological: RSV/hMPV/PIV3 formulation 1 at low dose
Biological: RSV/hMPV/PIV3 formulation 2 at low dose
Biological: RIV4 (Supemtek®)

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-27

Lead Sponsor: Sanofi

Target Recruit Count: 270

Registration Number: NCT06850051

Locations: 🇦🇺
University of Sunshine Coast Clinical Trials, South Brisbane, Queensland, Australia
🇦🇺
Griffith University, Southport, Queensland, Australia
🇦🇺
Emeritus Research, Camberwell, Victoria, Australia

and more 1 locations

Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years

Phase 1

Recruiting

Conditions: Chlamydia Trachomatis Immunization

Interventions: Biological: Chlamydia mRNA Vaccine
Other: Placebo

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-30

Lead Sponsor: Sanofi

Target Recruit Count: 1560

Registration Number: NCT06891417

Locations: 🇦🇺
Investigational Site Number : 0360001, Albion, Australia

Description of Patients With Type 1 Diabetes Treated With Teplizumab

Recruiting

Conditions: Type 1 Diabetes

Interventions: Drug: Teplizumab

First Posted Date: 2025-03-24

Last Posted Date: 2025-05-07

Lead Sponsor: Sanofi

Target Recruit Count: 100

Registration Number: NCT06892002

Locations: 🇺🇸
AM Diabetes & Endocrinology Center, Bartlett, Tennessee, United States
🇺🇸
Atlanta Diabetes Associates, Atlanta, Georgia, United States
🇺🇸
Ten's Medical PC, Staten Island, New York, United States

and more 2 locations

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis

Phase 2

Recruiting

Conditions: Colitis Ulcerative

Interventions: Drug: SAR441566
Drug: SAR441566 matching Placebo

First Posted Date: 2025-03-10

Last Posted Date: 2025-04-24

Lead Sponsor: Sanofi

Target Recruit Count: 204

Registration Number: NCT06867094

Locations: 🇺🇸
Connecticut Clinical Research Institute- Site Number : 8400017, Bristol, Connecticut, United States
🇺🇸
Wellness Clinical Research - Miami Lakes- Site Number : 8400002, Miami Lakes, Florida, United States
🇺🇸
GI Alliance - Glenview- Site Number : 8400005, Glenview, Illinois, United States

and more 5 locations

Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP

Phase 3

Recruiting

Conditions: Polyneuropathy, Inflammatory Demyelinating, Chronic

Interventions: Drug: Riliprubart Prefilled Pen (PFP)

First Posted Date: 2025-03-05

Last Posted Date: 2025-04-29

Lead Sponsor: Sanofi

Target Recruit Count: 300

Registration Number: NCT06859099

Locations: 🇨🇦
Investigational Site Number : 1240001, Gatineau, Quebec, Canada
🇨🇳
Investigational Site Number : 1560001, Shanghai, China
🇨🇳
Investigational Site Number : 1560003, Wuhan, China

A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 50 Years of Age With Non-congenital Myotonic Dystrophy Type 1

Phase 1

Not yet recruiting

Conditions: Myotonic Dystrophy

Interventions: Biological: SAR446268

First Posted Date: 2025-02-25

Last Posted Date: 2025-03-12

Lead Sponsor: Sanofi

Target Recruit Count: 32

Registration Number: NCT06844214

French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)

Recruiting

Conditions: Atopic Dermatitis

First Posted Date: 2025-02-20

Last Posted Date: 2025-02-20

Lead Sponsor: Sanofi

Target Recruit Count: 600

Registration Number: NCT06837454

Locations: 🇫🇷
Investigational Site Number 00001, Le Puy-en-Velay, France

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

Phase 3

Recruiting

Conditions: Chronic Rhinosinusitis With Nasal Polyps

Interventions: Drug: Itepekimab (SAR440340)
Drug: Placebo
Drug: Mometasone furoate nasal spray (MFNS)

First Posted Date: 2025-02-19

Last Posted Date: 2025-05-15

Lead Sponsor: Sanofi

Target Recruit Count: 210

Registration Number: NCT06834360

Locations: 🇺🇸
Ear and Sinus Institute- Site Number : 8400048, Fort Worth, Texas, United States
🇨🇱
Investigational Site Number : 1520001, Concepción, Biobío, Chile
🇨🇳
Investigational Site Number : 1560020, Baotou, China

and more 19 locations

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

Phase 3

Recruiting

Conditions: Chronic Rhinosinusitis With Nasal Polyps

Interventions: Drug: Itepekimab (SAR440340)
Drug: Mometasone furoate nasal spray (MFNS)
Drug: Placebo

First Posted Date: 2025-02-19

Last Posted Date: 2025-05-15

Lead Sponsor: Sanofi

Target Recruit Count: 210

Registration Number: NCT06834347

Locations: 🇺🇸
Sensa Health- Site Number : 8400038, Los Angeles, California, United States
🇺🇸
Newport Native MD- Site Number : 8400031, Newport Beach, California, United States
🇺🇸
Breathe Clear Institute for Sinus and Allergy Relief- Site Number : 8400040, Torrance, California, United States

and more 17 locations

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Phase 3

Recruiting

Conditions: Pneumococcal Immunization

Interventions: Biological: PCV21 vaccine
Biological: Prevnar 20 vaccine
Biological: M-M-R II vaccine
Biological: Rotarix
Biological: RotaTeq
Biological: Vaxelis vaccine
Biological: Varivax
Biological: Priorix
Biological: VAQTA
Biological: Havrix

First Posted Date: 2025-02-13

Last Posted Date: 2025-05-09

Lead Sponsor: Sanofi

Target Recruit Count: 580

Registration Number: NCT06824181

Locations: 🇺🇸
The Medici Medical Research- Site Number : 8400008, Hollywood, Florida, United States
🇺🇸
Atlantis Clinical Research, LLC- Site Number : 8400009, Miami, Florida, United States
🇺🇸
Helios- Site Number : 8400016, Burleson, Texas, United States

and more 8 locations

Home Terms & Conditions Privacy Policy